TYRA PEER ANALYSIS

Tyra Biosciences Inc — metric-by-metric comparison with peers and the industry median

TYRATyra Biosciences Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
TYRAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
TYRA+204.7%TLX-29.5%MSB+27.6%CSL-48.2%RTALB+24.1%
Year-to-Date (YTD)
TYRA+16.5%TLX+50.7%MSB-24.3%CSL-28.5%RTALB+5.0%

Key Metric Comparison

P/E

Lower is better
TYRATLXMSBCSL29.44RTALB4.89Median 17.91

ROE

Higher is better
TYRA-36.9%TLX-1.8%MSB-11.3%CSL7.7%RTALB15.1%Median -47.5%

Net Margin

Higher is better
TYRATLX-0.9%MSB-115.3%CSL9.2%RTALB136.3%Median -125.7%

Revenue Growth

Higher is better
TYRA-100.0%TLX56.3%MSB410.4%CSL4.8%RTALB24.0%Median 5.1%

All Metrics

Valuation
MetricTYRATLXMSBCSLRTALBInd. Median
P/E29.444.8917.91
P/B4.886.372.200.613.51
EV/EBITDA120.1410.2174.6114.82
P/S3.2431.612.626.6710.89
Financial Health
MetricTYRATLXMSBCSLRTALBInd. Median
Current Ratio20.491.432.571.215.90
Debt/Equity1.5%112.3%67.4%1.2%10.9%
NetDebt/EBITDA2.8913.132.220.901.15
Profitability
MetricTYRATLXMSBCSLRTALBInd. Median
Net Margin-0.9%-115.3%9.2%136.3%-125.7%
ROE-36.9%-1.8%-11.3%7.7%15.1%-47.5%
ROA-34.7%-0.7%-8.6%3.8%13.1%-35.8%
EBITDA Margin3.0%-76.6%32.8%9.0%-105.8%
Growth + Dividend
MetricTYRATLXMSBCSLRTALBInd. Median
Rev. Growth-100.0%56.3%410.4%4.8%24.0%5.1%
NI Growth-39.4%134.0%12.1%
Div. Yield0.0%2.5%0.0%0.2%
Payout0.0%103.1%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on TYRA

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.